Dosing & Uses
Dosage Forms & Strengths
tablet
- 5mg
- 7.5mg
- 10mg
- 15mg
- 30mg
Anxiety Disorders
10-15 mg/day PO divided q8-12hr; may increase every 2-3 days by 5 mg/day to 15-30 mg/day PO divided q8-12hr; not to exceed 60 mg/day
Smoking Cessation (Off-label)
30-60 mg/day PO for 9-13 weeks; begin 2-3 weeks before quit date
Dosing Modifications
Renal impairment: Not recommended for patients with severe impairment
Hepatic impairment: Not recommended for patients with severe impairment
Dosage Forms & Strengths
tablet
- 5mg
- 7.5mg
- 10mg
- 15mg
- 30mg
Generalized Anxiety Disorder (Off-label)
Pre-adolescent: 2.5-5 mg PO qDay; may increase dose by 2.5 mg every 3-4 days; not to exceed 20 mg/day
Adolescent: 5-10 mg PO qDay; may increase by 5 mg/day at weekly intervals PRN; not to exceed 60 mg/day divided q8-12hr
Dosing Modifications
Renal impairment: Not recommended for patients with severe impairment
Hepatic impairment: Not recommended for patients with severe impairment
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (6)
- isocarboxazid
isocarboxazid and buspirone both increase serotonin levels. Contraindicated.
isocarboxazid, buspirone. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. - linezolid
linezolid, buspirone. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
- phenelzine
phenelzine and buspirone both increase serotonin levels. Contraindicated.
phenelzine, buspirone. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. - procarbazine
procarbazine and buspirone both increase serotonin levels. Contraindicated. Combination is contraindicated within 2 weeks of MAOI use.
procarbazine, buspirone. Other (see comment). Contraindicated. Comment: Concomitant use of buspirone with MAOIs can increase blood pressure; this combination should be avoided. - selegiline transdermal
selegiline transdermal, buspirone. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
- tranylcypromine
tranylcypromine and buspirone both increase serotonin levels. Contraindicated.
tranylcypromine, buspirone. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
Serious - Use Alternative (57)
- amitriptyline
amitriptyline and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- amoxapine
amoxapine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- apalutamide
apalutamide will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.
- benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen, buspirone. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- carbamazepine
carbamazepine will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- cimetidine
cimetidine will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- citalopram
citalopram and buspirone both increase serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.
- clarithromycin
clarithromycin will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- clomipramine
clomipramine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- desipramine
desipramine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- desvenlafaxine
buspirone and desvenlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.
- dextromethorphan
buspirone and dextromethorphan both increase serotonin levels. Avoid or Use Alternate Drug.
- doxepin
doxepin and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- duloxetine
duloxetine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- erythromycin base
erythromycin base will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- erythromycin ethylsuccinate
erythromycin ethylsuccinate will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- erythromycin lactobionate
erythromycin lactobionate will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- erythromycin stearate
erythromycin stearate will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- escitalopram
escitalopram and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- fexinidazole
fexinidazole will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.
- fluoxetine
fluoxetine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- fluvoxamine
fluvoxamine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- hydrocodone
hydrocodone, buspirone. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- idelalisib
idelalisib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates
- imipramine
imipramine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- ivosidenib
ivosidenib will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.
- levomilnacipran
levomilnacipran and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- linezolid
linezolid and buspirone both increase serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
- lofepramine
lofepramine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- lonafarnib
lonafarnib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with sensitive CYP3A substrates. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling.
- lopinavir
lopinavir will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- lorcaserin
buspirone and lorcaserin both increase serotonin levels. Avoid or Use Alternate Drug.
- maprotiline
maprotiline and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- meperidine
buspirone and meperidine both increase serotonin levels. Avoid or Use Alternate Drug.
- methylene blue
methylene blue and buspirone both increase serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first.
- metoclopramide intranasal
buspirone, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
- milnacipran
milnacipran and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- nefazodone
nefazodone and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- nortriptyline
nortriptyline and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- olopatadine intranasal
buspirone and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- paroxetine
paroxetine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- protriptyline
protriptyline and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- rasagiline
rasagiline, buspirone. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of acute hypertensive episode. Avoid combination within 14 days of MAOI use.
- rifabutin
rifabutin will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- rifampin
rifampin will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- selegiline
selegiline and buspirone both increase serotonin levels. Avoid or Use Alternate Drug. Concurrent use is not recommended. Risk of acute hypertensive episodes.
- selegiline transdermal
selegiline transdermal and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- selinexor
selinexor, buspirone. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.
- sertraline
sertraline and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- St John's Wort
St John's Wort will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
buspirone and St John's Wort both increase serotonin levels. Avoid or Use Alternate Drug. - sufentanil SL
sufentanil SL, buspirone. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- trazodone
trazodone and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- trimipramine
trimipramine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- tucatinib
tucatinib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling.
- venlafaxine
venlafaxine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- vilazodone
buspirone, vilazodone. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated. .
- voxelotor
voxelotor will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.
Monitor Closely (132)
- 5-HTP
5-HTP and buspirone both increase serotonin levels. Modify Therapy/Monitor Closely.
- almotriptan
almotriptan and buspirone both increase serotonin levels. Modify Therapy/Monitor Closely.
- amobarbital
amobarbital will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- aprepitant
aprepitant will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- armodafinil
armodafinil will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- artemether/lumefantrine
artemether/lumefantrine will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- atazanavir
atazanavir will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- belzutifan
belzutifan will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information.
- bosentan
bosentan will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- brexanolone
brexanolone, buspirone. Either increases toxicity of the other by sedation. Use Caution/Monitor.
- budesonide
budesonide will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- buprenorphine, long-acting injection
buspirone increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.
- butabarbital
butabarbital will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- butalbital
butalbital will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- cenobamate
cenobamate will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate.
cenobamate, buspirone. Either increases effects of the other by sedation. Use Caution/Monitor. - ceritinib
ceritinib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- cobicistat
cobicistat will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. A decreased dose of buspirone may be required
- cocaine topical
buspirone and cocaine topical both increase serotonin levels. Modify Therapy/Monitor Closely.
- conivaptan
conivaptan will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- cortisone
cortisone will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- crizotinib
crizotinib increases levels of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
- crofelemer
crofelemer increases levels of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.
- cyclosporine
cyclosporine will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- dabrafenib
dabrafenib will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.
- daridorexant
buspirone and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- darifenacin
darifenacin will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- darunavir
darunavir will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- dasatinib
dasatinib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- deferasirox
deferasirox will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- dexamethasone
dexamethasone will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- dexfenfluramine
buspirone and dexfenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.
- dextroamphetamine
buspirone and dextroamphetamine both increase serotonin levels. Modify Therapy/Monitor Closely.
- dextroamphetamine transdermal
buspirone, dextroamphetamine transdermal. Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s).
- DHEA, herbal
DHEA, herbal will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- difelikefalin
difelikefalin and buspirone both increase sedation. Use Caution/Monitor.
- dihydroergotamine
buspirone and dihydroergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.
- dihydroergotamine intranasal
buspirone and dihydroergotamine intranasal both increase serotonin levels. Modify Therapy/Monitor Closely.
- diltiazem
diltiazem will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of buspirone with diltiazem may increase plasma concentrations and/or toxicities of buspirone. Dose adjustments may be necessary.
- dronedarone
dronedarone will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- duvelisib
duvelisib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. will increase the level or effect of
- efavirenz
efavirenz will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- elagolix
elagolix will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.
- eletriptan
eletriptan and buspirone both increase serotonin levels. Modify Therapy/Monitor Closely.
- elvitegravir/cobicistat/emtricitabine/tenofovir DF
elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.
- encorafenib
encorafenib, buspirone. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.
- enzalutamide
enzalutamide will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- ergotamine
buspirone and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.
- esketamine intranasal
esketamine intranasal, buspirone. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.
- eslicarbazepine acetate
eslicarbazepine acetate will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- etravirine
etravirine will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- fedratinib
fedratinib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.
- fenfluramine
buspirone and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.
- fluconazole
fluconazole will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- fludrocortisone
fludrocortisone will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- fluvoxamine
fluvoxamine will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- fosamprenavir
fosamprenavir will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- fosaprepitant
fosaprepitant will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- fosphenytoin
fosphenytoin will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- frovatriptan
frovatriptan and buspirone both increase serotonin levels. Modify Therapy/Monitor Closely.
- gabapentin
gabapentin, buspirone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- gabapentin enacarbil
gabapentin enacarbil, buspirone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- ganaxolone
buspirone and ganaxolone both increase sedation. Use Caution/Monitor.
- gepirone
gepirone and buspirone both increase serotonin levels. Use Caution/Monitor. Monitor for symptoms of serotonin syndrome when gepirone is used gepirone with other drugs that may affect the serotonergic neurotransmitter systems. If serotonin syndrome occurs, consider discontinue gepirone and/or concomitant serotonergic drug.
- grapefruit
grapefruit will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- griseofulvin
griseofulvin will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- hydrocortisone
hydrocortisone will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- iloperidone
iloperidone increases levels of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.
- indinavir
indinavir will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- ioflupane I 123
buspirone decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.
- isoniazid
isoniazid will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
buspirone and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely. - istradefylline
istradefylline will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.
- itraconazole
itraconazole will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Limit buspirone dose 2.5 mg/da. Monitor for increased buspirone effects/toxicities when combined with strong CYP3A4 inhibitors.
- ketoconazole
ketoconazole will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce starting dose of buspirone to 2.5 mg PO qDay. Adjust dose based on clinical assessment.
- L-tryptophan
buspirone and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.
- lapatinib
lapatinib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- lasmiditan
lasmiditan, buspirone. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
- lemborexant
lemborexant, buspirone. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.
- lenacapavir
lenacapavir will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir (a moderate CYP3A4 inhibitor) may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.
- letermovir
letermovir increases levels of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- levoketoconazole
levoketoconazole will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce starting dose of buspirone to 2.5 mg PO qDay. Adjust dose based on clinical assessment.
- lisdexamfetamine
buspirone, lisdexamfetamine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue along with concomitant serotonergic drug(s).
- lithium
buspirone and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.
- lorlatinib
lorlatinib will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- lsd
buspirone and lsd both increase serotonin levels. Modify Therapy/Monitor Closely.
- lumefantrine
lumefantrine will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- lurasidone
lurasidone, buspirone. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.
- marijuana
marijuana will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- methylprednisolone
methylprednisolone will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- metronidazole
metronidazole will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- miconazole vaginal
miconazole vaginal will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- midazolam intranasal
midazolam intranasal, buspirone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.
- mifepristone
mifepristone will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If buspirone needs to be administered concurrently, a low dose of buspirone (ie, 2.5 mg PO twice daily) recommended initially; base subsequent dosage adjustments on clinical response
- mirtazapine
buspirone and mirtazapine both increase serotonin levels. Modify Therapy/Monitor Closely.
- mitotane
mitotane decreases levels of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.
- morphine
buspirone and morphine both increase serotonin levels. Modify Therapy/Monitor Closely.
- naratriptan
naratriptan and buspirone both increase serotonin levels. Modify Therapy/Monitor Closely.
- nefazodone
nefazodone will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.
- nelfinavir
nelfinavir will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- nevirapine
nevirapine will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- nifedipine
nifedipine will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- nilotinib
nilotinib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- oliceridine
oliceridine, buspirone. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- oxcarbazepine
oxcarbazepine will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- pentazocine
buspirone and pentazocine both increase serotonin levels. Modify Therapy/Monitor Closely.
- pentobarbital
pentobarbital will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- phenobarbital
phenobarbital will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- phenytoin
phenytoin will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- posaconazole
posaconazole will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- prednisone
prednisone will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- pregabalin
pregabalin, buspirone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- primidone
primidone will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- quinupristin/dalfopristin
quinupristin/dalfopristin will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- ribociclib
ribociclib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- rifapentine
rifapentine will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- ritonavir
ritonavir will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- rizatriptan
rizatriptan and buspirone both increase serotonin levels. Modify Therapy/Monitor Closely.
- rucaparib
rucaparib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated.
- rufinamide
rufinamide will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- SAMe
buspirone and SAMe both increase serotonin levels. Modify Therapy/Monitor Closely.
- saquinavir
saquinavir will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- secobarbital
secobarbital will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- stiripentol
stiripentol, buspirone. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment.
- sumatriptan
sumatriptan and buspirone both increase serotonin levels. Modify Therapy/Monitor Closely.
- sumatriptan intranasal
sumatriptan intranasal and buspirone both increase serotonin levels. Modify Therapy/Monitor Closely.
- tazemetostat
tazemetostat will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- tecovirimat
tecovirimat will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered.
- topiramate
topiramate will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- tramadol
buspirone and tramadol both increase serotonin levels. Modify Therapy/Monitor Closely.
- verapamil
verapamil will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Consider lower buspirone doses.
- voriconazole
voriconazole will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- zafirlukast
zafirlukast will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- zolmitriptan
zolmitriptan and buspirone both increase serotonin levels. Modify Therapy/Monitor Closely.
Minor (4)
- acetazolamide
acetazolamide will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- anastrozole
anastrozole will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- cyclophosphamide
cyclophosphamide will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- larotrectinib
larotrectinib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
Adverse Effects
>10%
Dizziness (12%)
1-10%
Drowsiness (10%)
Nausea (8%)
Headache (6%)
Nervousness (5%)
Blurred vision (2%)
Confusion (2%)
Diarrhea (2%)
Excitement (2%)
Insomnia (2%)
Myalgia (1%)
Numbness (2%)
Paresthesia (1%)
Rash (1%)
Tremor (1%)
Weakness (2%)
Nasal congestion (1%)
Sore throat (1%)
Nonspecific chest pain (1%)
Tinnitus (1%)
Dream disturbances (1%)
<1%
Akathisia
Allergic reaction
Anorexia
Bruising
Galactorrhea
Heart failure
Menstrual irregularity
Suicidal ideation
Syncope
Alopecia
Eosinophilia
Edema
Enuresis
Increased ocular pressure
Visual disturbances
Rectal bleeding
Photophobia
Dystonia
Warnings
Contraindications
Hypersensitivity
Cautions
Do not use PRN for anxiety
Will not prevent withdrawal from other anxiolytics, such as benzodiazepine
May cause cognitive motor impairment
Restlessness syndrome associated with therapy
Use in severe renal/hepatic impairment not recommended
Use with MAO inhibitors may result in hypertensive reaction (use not recommended)
Pregnancy & Lactation
Pregnancy category: B
Lactation: Excretion in milk unknown/not recommended
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Is an azaspirodecanedione; high affinity for serotonin 5HT1A and 5HT2 receptors and moderate affinity for dopamine D2 receptors, but no effect on benzodiazepine GABA receptors
No anticonvulsant, muscle relaxant, or sedative effects
Absorption
Bioavailability: ~4%
Onset: 2-4 wk (anxiolytic effects)
Peak serum time: 40-90 min
Peak plasma concentration: 1-6 ng/mL
Distribution
Protein bound: 86%
Vd: 5.3 L/kg
Metabolism
Hepatic metabolism by CYP3A4
Metabolites: 1-pyrimidinylpiperazine (1-PP)
Elimination
Half-life: 2-3 hr
Excretion: Urine (29-63%); feces (18-38%)
Total body clearance: 28 mL/min/kg
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| buspirone oral - | 10 mg tablet |  | |
| buspirone oral - | 5 mg tablet |  | |
| buspirone oral - | 15 mg tablet |  | |
| buspirone oral - | 10 mg tablet |  | |
| buspirone oral - | 15 mg tablet |  | |
| buspirone oral - | 30 mg tablet |  | |
| buspirone oral - | 5 mg tablet |  | |
| buspirone oral - | 5 mg tablet |  | |
| buspirone oral - | 5 mg tablet |  | |
| buspirone oral - | 7.5 mg tablet |  | |
| buspirone oral - | 30 mg tablet |  | |
| buspirone oral - | 30 mg tablet |  | |
| buspirone oral - | 5 mg tablet |  | |
| buspirone oral - | 15 mg tablet |  | |
| buspirone oral - | 5 mg tablet |  | |
| buspirone oral - | 15 mg tablet |  | |
| buspirone oral - | 15 mg tablet |  | |
| buspirone oral - | 15 mg tablet |  | |
| buspirone oral - | 5 mg tablet |  | |
| buspirone oral - | 10 mg tablet |  | |
| buspirone oral - | 15 mg tablet |  | |
| buspirone oral - | 10 mg tablet |  | |
| buspirone oral - | 7.5 mg tablet |  | |
| buspirone oral - | 10 mg tablet |  | |
| buspirone oral - | 10 mg tablet |  | |
| buspirone oral - | 30 mg tablet |  | |
| buspirone oral - | 15 mg tablet |  | |
| buspirone oral - | 7.5 mg tablet |  | |
| buspirone oral - | 5 mg tablet |  | |
| buspirone oral - | 30 mg tablet |  | |
| buspirone oral - | 10 mg tablet |  | |
| buspirone oral - | 5 mg tablet |  | |
| buspirone oral - | 10 mg tablet |  | |
| buspirone oral - | 30 mg tablet |  | |
| buspirone oral - | 15 mg tablet |  | |
| buspirone oral - | 7.5 mg tablet |  | |
| buspirone oral - | 7.5 mg tablet |  | |
| buspirone oral - | 7.5 mg tablet |  | |
| buspirone oral - | 10 mg tablet |  | |
| buspirone oral - | 7.5 mg tablet |  | |
| buspirone oral - | 5 mg tablet |  | |
| buspirone oral - | 30 mg tablet |  | |
| buspirone oral - | 5 mg tablet |  | |
| buspirone oral - | 30 mg tablet |  | |
| buspirone oral - | 30 mg tablet |  | |
| buspirone oral - | 10 mg tablet |  | |
| buspirone oral - | 30 mg tablet |  | |
| buspirone oral - | 5 mg tablet |  | |
| buspirone oral - | 15 mg tablet |  | |
| buspirone oral - | 15 mg tablet |  | |
| buspirone oral - | 15 mg tablet |  | |
| buspirone oral - | 7.5 mg tablet |  | |
| buspirone oral - | 7.5 mg tablet |  | |
| buspirone oral - | 10 mg tablet |  | |
| buspirone oral - | 10 mg tablet |  | |
| buspirone oral - | 10 mg tablet |  | |
| buspirone oral - | 10 mg tablet |  | |
| buspirone oral - | 10 mg tablet |  | |
| buspirone oral - | 15 mg tablet |  | |
| buspirone oral - | 30 mg tablet |  | |
| buspirone oral - | 7.5 mg tablet |  | |
| buspirone oral - | 30 mg tablet |  | |
| buspirone oral - | 15 mg tablet |  | |
| buspirone oral - | 5 mg tablet |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
buspirone oral
BUSPIRONE - ORAL
(bue-SPYE-rone)
COMMON BRAND NAME(S): Buspar
USES: This medication is used to treat anxiety. It may help you think more clearly, relax, worry less, and take part in everyday life. It may also help you to feel less jittery and irritable, and may control symptoms such as trouble sleeping, sweating, and pounding heartbeat. Buspirone is a medication for anxiety (anxiolytic) that works by affecting certain natural substances in the brain (neurotransmitters).
HOW TO USE: Take this medication by mouth as directed by your doctor, usually 2 or 3 times a day. You may take this medication with or without food, but it is important to choose one way and always take it the same way so that the amount of drug absorbed will always be the same.Buspirone may come in a tablet that can be split to get the correct dose for you. Follow the manufacturer's Patient Instruction Sheet or ask your pharmacist how to split the tablet to get your dose.Avoid eating grapefruit or drinking grapefruit juice while using this medication unless your doctor or pharmacist says you may do so safely. Grapefruit can increase the chance of side effects with this medicine. Ask your doctor or pharmacist for more details.Dosage is based on your medical condition and response to therapy. Use this medication regularly in order to get the most benefit from it. To help you remember, use it at the same times each day. When this medication is started, symptoms of anxiety (such as restlessness) may sometimes get worse before they improve. It may take up to a month or more to get the full effect of this medication.Inform your doctor if your symptoms last or get worse.
SIDE EFFECTS: Dizziness, drowsiness, headache, nausea, nervousness, lightheadedness, restlessness, blurred vision, tiredness, and trouble sleeping may occur. If any of these effects last or get worse, notify your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Rarely, patients taking buspirone may develop movement disorders such as shakiness (tremors), muscle stiffness, mask-like facial expression, jerky walking movements, or a condition known as tardive dyskinesia. In some cases, these conditions may be permanent. Tell your doctor right away if you develop any unusual/uncontrolled movements (especially of the face, mouth, tongue, arms, or legs).Get medical help right away if you have any very serious side effects, including: easy bleeding/bruising, shortness of breath, chest pain, fast/irregular heartbeat.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist .In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before taking buspirone, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney problems, liver problems, bipolar disorder (manic-depression), Parkinson's disease.This drug may make you dizzy or drowsy. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Avoid alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).If you are taking other medications for anxiety, do not suddenly stop them unless directed by your doctor. Buspirone will not prevent withdrawal symptoms from other medications, and your dose may need to be lowered slowly when you switch to buspirone. Discuss your treatment plan with your doctor. If you experience withdrawal symptoms, tell your doctor right away.During pregnancy, this medication should only be used when clearly needed. Tell your doctor if you are pregnant before using this medication. Discuss the risks and benefits with your doctor.It is unknown if this drug passes into breast milk. However, similar drugs pass into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breastfeeding.
DRUG INTERACTIONS: See also How to Use section.Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug are: antidepressants (including SSRIs such as fluoxetine, tricyclic antidepressants such as amitriptyline/nortriptyline, trazodone), haloperidol.Taking MAO inhibitors with this medication may cause a serious (possibly fatal) drug interaction. Avoid taking MAO inhibitors (isocarboxazid, linezolid, metaxalone, methylene blue, moclobemide, phenelzine, procarbazine, rasagiline, safinamide, selegiline, tranylcypromine) during treatment with this medication. Most MAO inhibitors should also not be taken for two weeks before and after treatment with this medication. Ask your doctor when to start or stop taking this medication.Other medications can affect the removal of buspirone from your body, which may affect how buspirone works. Examples include azole antifungals (such as itraconazole), corticosteroids (such as dexamethasone), diltiazem, nefazodone, rifamycins (such as rifabutin), ritonavir, drugs used to treat seizures (such as phenytoin, phenobarbital), among others.Tell your doctor or pharmacist if you are taking other products that cause drowsiness such as opioid pain or cough relievers (such as codeine, hydrocodone), alcohol, marijuana (cannabis), drugs for sleep or anxiety (such as alprazolam, lorazepam, zolpidem), muscle relaxants (such as carisoprodol, cyclobenzaprine), or antihistamines (such as cetirizine, diphenhydramine).Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely.This medication may interfere with certain medical/lab tests (such as brain scan for Parkinson's disease), possibly causing false test results. Make sure lab personnel and all your doctors know you use this drug.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: Do not share this medication with others.Keep all medical and lab appointments.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised May 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
